Efficacy of intravenous Lidocaine in prevention of coughing and sore throat after general anesthesia

Efficacy of intravenous 0.5 mg/kg or 0.25 mg/kg of Lidocaine in prevention of coughing and sore throat after awakening from general anesthesia

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20180420005

Enrollment

Registered

2018-04-20

Start date

2018-04-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cough and sore throat after general anesthesia

Interventions

smaller dose from usual dosage in clinical practice,clinical practice dosage

Experimental Drug,Active Comparator Drug

0.25 mg/Kg IV lidocaine,0.5 mg/kg IV lidocaine

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: general anesthesia with endotracheal tube ASA 1-2 accept to the study

Exclusion criteria

Exclusion criteria: allergy to lidocaine comorbiditie : heart disease,chronic liver disease,chronic kidney disease pregnant

Design outcomes

Primary

Measure	Time frame
coughing after general anesthesia 12 month severity of coughing (mild,moderate,severe)	—

Secondary

Measure	Time frame
sore throat after general anesthesia 12 month degree of pain (mild,moderate,sever)	—

Countries

Thailand

Contacts

Public ContactSithapan Munjupong

Phramongkutklao hospital

sithapan@gmail.com0991959255

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026